Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.

Autor: Pier Woudstra, Peter Damman, Wichert J Kuijt, Wouter J Kikkert, Maik J Grundeken, Peter M van Brussel, An K Stroobants, Jan P van Straalen, Johan C Fischer, Karel T Koch, José P S Henriques, Jan J Piek, Jan G P Tijssen, Robbert J de Winter

Publikováno v: PLoS ONE, Vol 9, Iss 5, p e96251 (2014)

BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity is a biomarker predicting cardiovascular diseases in a real-world. However, the prognostic value in patients undergoing primary percutaneous coronary intervention (pPCI) for ST-se

Externí odkaz: https://doaj.org/article/24a1b548da354adf84337f2e9715c24f

ACTION-1: study protocol for a randomised controlled trial on ACT-guided heparinization during open abdominal aortic aneurysm repair

Autor: Arno M. Wiersema, Liliane C. Roosendaal, Mark J. W. Koelemaij, Jan G. P. Tijssen, Susan van Dieren, Jan D. Blankensteijn, E. Sebastian Debus, Saskia Middeldorp, Jan M. M. Heyligers, Ymke S. Fokma, Michel M. P. J. Reijnen, Vincent Jongkind

Publikováno v: Trials, Vol 22, Iss 1, Pp 1-16 (2021)

Abstract Background Heparin is used worldwide for 70 years during all non-cardiac arterial procedures (NCAP) to reduce thrombo-embolic complications (TEC). But heparin also increases blood loss causing possible harm for the patient. Heparin has an un

Externí odkaz: https://doaj.org/article/960975c75da441748afb415e14ef7f44

The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial

Autor: Amber van Broekhoven, Niekbachsh Mohammadnia, Max J. M. Silvis, Jonathan Los, Aernoud T. L. Fiolet, Tjerk S. J. Opstal, Arend Mosterd, John W. Eikelboom, Stefan M. Nidorf, Charley A. Budgeon, Elizabeth Byrnes, Willem A. Bax, Jan G. P. Tijssen, Dominique P. V. de Kleijn, Peter L. Thompson, Saloua El Messaoudi, Jan H. Cornel

Publikováno v: Clinical drug investigation, 42(11), 977-985. Adis International Ltd
Clinical Drug Investigation, 42, 977-985
Clinical Drug Investigation, 42, 11, pp. 977-985

Contains fulltext : 288089.pdf (Publisher’s version ) (Open Access) BACKGROUND AND OBJECTIVE: The Low-Dose Colchicine-2 (LoDoCo2) trial showed that 2-4 years exposure to colchicine 0.5 mg once daily reduced the risk of cardiovascular events in pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a7e75f557f8750b00f611a1192bac17
https://research.vumc.nl/en/publications/94450c2a-4c60-47b0-a72e-c9b9f640b416

Colchicine in patients with chronic coronary disease

Autor: Stefan M, Nidorf, Aernoud T L, Fiolet, Arend, Mosterd, John W, Eikelboom, Astrid, Schut, Tjerk S J, Opstal, Salem H K, The, Xiao-Fang, Xu, Mark A, Ireland, Timo, Lenderink, Donald, Latchem, Pieter, Hoogslag, Anastazia, Jerzewski, Peter, Nierop, Alan, Whelan, Randall, Hendriks, Henk, Swart, Jeroen, Schaap, Aaf F M, Kuijper, Maarten W J, van Hessen, Pradyot, Saklani, Isabel, Tan, Angus G, Thompson, Allison, Morton, Chris, Judkins, Willem A, Bax, Maurits, Dirksen, Marco, Alings, Graeme J, Hankey, Charley A, Budgeon, Jan G P, Tijssen, Jan H, Cornel, Peter L, Thompson, Karen, Youl

Publikováno v: LoDoCo2 Trial Investigators 2020, ' Colchicine in patients with chronic coronary disease ', New England Journal of Medicine, vol. 383, no. 19, pp. 1838-1847 . https://doi.org/10.1056/NEJMoa2021372
The New England Journal of Medicine, 383, 1838-1847
The New England Journal of Medicine, 383, 19, pp. 1838-1847
New England journal of medicine, 383(19), 1838-1847. Massachussetts Medical Society
New England Journal of Medicine, 383(19), 1838-1847. Massachussetts Medical Society

Evidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial infarction, but evidence of such a risk reduction in patients with chronic coronary dis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7d9279d0223f45562c25fafd74b3706
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85090986302&origin=inward

Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation

Autor: Ruben R De With, Michiel Rienstra, Marcelle D Smit, Bob Weijs, Victor W Zwartkruis, Anne H Hobbelt, Marco Alings, Jan G P Tijssen, Johan Brügemann, Bastiaan Geelhoed, Hans L Hillege, Raymond Tukkie, Martin E Hemels, Robert G Tieleman, Adelita V Ranchor, Dirk J Van Veldhuisen, Harry J G M Crijns, Isabelle C Van Gelder

Publikováno v: Europace, 21(4), 563-571. Oxford University Press
Europace, 21, 4, pp. 563-571
EP Europace, 21(4), 563-571. Oxford University Press
Europace, 21, 563-571

AIMS: Atrial fibrillation (AF) reduces quality of life (QoL). We aim to evaluate effects of targeted therapy of underlying conditions on QoL in patients with AF and heart failure (HF). METHODS AND RESULTS: The Routine versus Aggressive risk factor dr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17eaf7678ba1b046220ff77ac6ac4f5e
https://research.rug.nl/en/publications/7adc12ca-bcda-4f45-9c6e-53ed15ba120e